Multiple Myeloma

7 protocols meet the specified criteria.
  • A061202

    A PHASE I/II STUDY OF POMALIDOMIDE, DEXAMETHASONE AND IXAZOMIB VS. POMALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA RELAPSING ON LENALIDOMIDE AS PART OF FIRST LINE THERAPY
  • CPX351-102

    A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies
  • EA9171

    Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
  • EAA173

    Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma
  • PRE0905

    Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
  • S1803

    Phase III Study of Daratumumab/rHuPH20 (NSC-810304) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
  • SIMPRO

    SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice.